Nanoconjugados formados por moléculas dendríticas y péptidos como agentes antitumorales frente al cáncer

The present invention relates to the formation of nanoconjugates exhibiting antitumour activity, mainly against advanced prostate cancer, but without excluding others. The nanoconjugates are formed from dendritic systems (dendrimers or dendrons) and neuropeptides. The dendritic molecules mainly have...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: DE LA MATA DE LA MATA, Francisco Javier, SANCHEZ MILLA, María, CARMENA SIERRA, Maria José, SANCHEZ-NIEVES FERNANDEZ, Javier, MUNOZ MORENO, Laura, GOMEZ RAMIREZ, Rafael
Format: Patent
Sprache:spa
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to the formation of nanoconjugates exhibiting antitumour activity, mainly against advanced prostate cancer, but without excluding others. The nanoconjugates are formed from dendritic systems (dendrimers or dendrons) and neuropeptides. The dendritic molecules mainly have a carbosilane structure with ammonium groups on the periphery. The peptides are preferably from the glucagon/secretin family (e.g.VIP, GHRH, PACAP). The combination of these two systems leads to a nanoconjugate with anticarcinogenic properties that differ from those of their individual precursors. The antitumour activity is reflected in the growth inhibition and death of tumour cells in advanced prostate cancer (PC3) and, in addition, said nanoconjugates favour cell adhesion and prevent tumour cell migration processes, in other words metastasis processes.